CD19嵌合抗原受体修饰的T细胞治疗治疗急慢性淋巴细胞白血病

icartab

CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia

Abstract

Adoptive cell therapy (ACT) for cancer represents a promising new treatment modality. ACT based on the administration of cytotoxic T cells genetically engineered to express a chimeric antigen receptor (CAR) recognizing CD19 expressed by B cell malignancies has been shown to induce complete lasting responses in patients with chronic lymphocytic leukaemia (CLL) and acute lymphoblastic leukaemia (ALL). So far, eleven clinical trials including 99 CLL and ALL patients treated with CAR T cells targeting CD19 have been published, and the results from these trials are promising with impressive clinical responses in heavily pretreated patients. Thus, CAR T cell therapy has induced complete responses in both CLL and ALL, and surprisingly, current results indicate that patients with ALL are more prone to respond than are CLL patients. Importantly, the majority of CAR cell studies have observed severe therapy-associated toxicities, which needs attention. Herein we review current data and discuss key aspects of this powerful approach to treat and potentially cure B cell malignancies.

CD-19嵌合抗原受体修饰的T细胞治疗治疗急慢性淋巴细胞白血病

摘要：

用过继细胞治疗（ACT）癌症代表着一个具有前景的新治疗方式。以T细胞毒性为基础的，表达识别B淋巴细胞表面CD19的CAR的过继细胞治疗已经在慢性淋巴细胞白血病和急性淋巴细胞白血病病人的治疗中显示出了完全持续的疗效。到目前为止，

到目前为止，共有十一个使用靶向CD19的CAR-T细胞的临床试验已经发布，包括99例CLL和ALL病人。这些临床实验的结果显示在严重的病人身上展现了很好的临床疗效。因此，CAR-T细胞治疗在CLL病人和ALL病人身上都有完全的疗效。而令人惊讶的是，研究结果表明，ALL病人的治疗更加有效。重要的是，大多数的CAR-T细胞研究已经观察到严重的治疗相关的毒性，需要注意。在这里，我们回顾了目前的数据，并讨论这个强大的治疗和潜在治愈B淋巴细胞白血病的方案的关键因素。

icartab

爱康得生物医学技术（苏州）有限公司，专注免疫治疗。
更多资讯，请关注http://www.icartab.com.cn/company_overview.html